News

Hunting productivity, drugmakers pitch new ‘pillars’ of R&D

Editor - 0
SAN FRANCISCO — Developing new medicines isn't a resource-efficient endeavor. Estimates vary, but most molecules selected to begin clinical development won't end up on pharmacy...
Read more
News

Novartis chief defends cell, gene therapy push

By most measures, Novartis enjoyed a positive start to 2019. Drug sales rose by 5% in dollar terms, lifted by strong performances from the Swiss pharma's...
Editor - 0
Read more
Drug Discovery

Gilead firms up path to market for key arthritis drug

A filing this year for filgotinib could set up a potential market launch in 2020, which would be one to two years earlier than some...
Editor - 0
Read more
Drug Discovery

Celgene wins approval for drug key to Bristol buyout

Editor - 0
Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 
Read more
News

Gilead to build manufacturing site in Maryland to boost cell therapy

Editor - 0
The new facility should help the big biotech meet some of the unique challenges of manufacturing CAR-T therapies. The process is complex and time...
Read more
News

PhRMA’s DTC defense rolls out on airwaves and online

Editor - 0
The move by PhRMA and its members to address calls for more transparency on drugs prices came to a head in October, when the...
Read more
News

FDA’s Woodcock defends accelerated approvals and talks of culture shift in clinical trials

Editor - 0
Over more than three decades at the Food and Drug Administration, Janet Woodcock has seen the biotech industry mature from the early days of...
Read more
Editor

Follow RXMonthly

News

Another late-stage miss knocks Gilead from its leading NASH...

News Editor - 0
Gilead is part of a small group of drugmakers with late-stage NASH assets. But misfires in the STELLAR program have dimmed the prospects of...
Read more

AbbVie deal for Allergan not about the taxes, thanks...

News Editor - 0
AbbVie CEO Rick Gonzalez finally achieved the overseas acquisition that he sought five years ago. But his deal for Allergan comes too late to...
Read more

FDA’s Woodcock defends accelerated approvals and talks of culture...

News Editor - 0
Over more than three decades at the Food and Drug Administration, Janet Woodcock has seen the biotech industry mature from the early days of...
Read more

Wave delays key data readout for Huntington’s therapy

News Editor - 0
Investors reacted negatively to the pushed-back readouts, sending shares of the Singapore-based biotech down nearly 20% between Tuesday's market close and Wednesday's. Wall Street analysts,...
Read more

Latest articles

News

CMS chief declines to provide details on Trump healthcare plan

The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...
Editor - 0
Read more
Drug Discovery

Roche cancer drug the 3rd approved for pan-tumor use

Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 
Editor - 0
Read more
Drug Discovery

Novo faces shareholder suit over insulin sales disclosures

Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...
Editor - 0
Read more
Drug Discovery

Celgene wins approval for drug key to Bristol buyout

Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 
Editor - 0
Read more
Load more

Subscribe to our newsletter

© Copyright - Newspaper by TagDiv